<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22623">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812290</url>
  </required_header>
  <id_info>
    <org_study_id>ATAGC 03</org_study_id>
    <nct_id>NCT02812290</nct_id>
  </id_info>
  <brief_title>Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation, a Multicenter Study</brief_title>
  <acronym>INTERLUNG</acronym>
  <official_title>Multi-Centric Observational Study to Analyze the Diagnostic Molecular Features in the Clinical Setting of Lung Allograft Biopsies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the potential impact of molecular phenotyping of transbronchial
      biopsies in lung transplant recipients with allograft dysfunction, and the potential for
      developing a safer endobronchial mucosal biopsy format.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard for biopsy-based diagnoses of dysfunction of lung transplants is the
      ISHLT classification applied to transbronchial biopsies, which represents an arbitrary
      international consensus. Recent data-driven approaches using molecular and conventional
      technologies indicate that this system produces frequently incorrect diagnoses with
      potential harm to patients due to inappropriate treatment. especially in relationship to the
      correct diagnosis of chronic lung allograft dysfunction is a pressing need. To address this
      unmet need and improve diagnostics in the area of organ transplantation, the Alberta
      Transplant Applied Genomics Centre (ATAGC, University of Alberta) has developed a new
      diagnostic system - the Molecular Microscope™ Diagnostic System (MMDx™) that interprets
      biopsies in terms of their molecular phenotype. The MMDx™, developed first in kidney
      transplant biopsies with well established phenotypes, will now be adapted to lung transplant
      transbronchial biopsies (TBBs). Microarray analysis of lung allograft biopsy specimens will
      be compared to conventional allograft phenotyping, including clinical, physiologic,
      radiographic and histological assessment. The present study will use the MMDx™ system to
      assess and report TBBs, and validate and refine this system in 300 unselected prospectively
      collected lung TBBs. A subset of the study will examine the third bifurcation mucosal
      endobronchial biopsies (3BMBs) paired with TBBs from 50 patients to see if the safer 3BMBs
      can substitute for the TBB to be used by MMDx™.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assign molecular scores (probability) of lung transplant disease in a reference set of 300 transbronchial biopsies.</measure>
    <time_frame>two years</time_frame>
    <description>Create molecular classifier that predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assign molecular scores (probability) of lung transplant disease in a reference set of 50 mucosal endobronchial biopsies.</measure>
    <time_frame>two years</time_frame>
    <description>Create molecular classifier that predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lung transplant biopsies taken as per local standard of care.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with functioning lung transplant biopsied to determine their graft dysfunction of
        to confirm good function as per standard of care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All lung transplant recipients undergoing a biopsy as determined by their surgeon or
             physician.

        Exclusion Criteria:

        Patients who declined participation or unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip F Halloran, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine and Dentistry, University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad S Famulski, PhD</last_name>
    <phone>1 780 492 1725</phone>
    <email>konrad@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Polakowski, PhD</last_name>
    <phone>1 780 492 5091</phone>
    <email>polakows@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>MD 21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina L Timofte, MD</last_name>
      <phone>216-334-7534</phone>
      <email>itimofte@medicine.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Irina L Timofte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Pulmonary and Critical Care, Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>MO 63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Kreisel, MD, PhD</last_name>
      <phone>314-362-6021</phone>
      <email>kreiseld@wudosis.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Kreisel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elbert Trulock, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramsey Hachem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital, Monash University</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Glen Westall, MD, PhD</last_name>
      <phone>+61 3 9076 2405</phone>
      <email>g.westall@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Glen Westall, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greg Snell, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Thoracic Surgery, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Walter Klepetko, MD, PhD</last_name>
      <phone>+43-1-40400-5644</phone>
    </contact>
    <investigator>
      <last_name>Walter Klepetko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Jaksch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Transplant Applied Genomics Centre, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konrad S Famulski, PhD</last_name>
      <phone>1 780 492 1725</phone>
      <email>konrad@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Philip F Halloran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kieran Halloran, MD</last_name>
      <phone>1 780 492 2691</phone>
      <email>kieran.halloran@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Kieran Halloran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaf Keshavjee, MD, MSc</last_name>
      <phone>1 416-340-3863</phone>
      <email>shaf.keshavjee@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Shaf Keshavjee, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 21, 2016</lastchanged_date>
  <firstreceived_date>May 31, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anitbody mediated rejection, T cell mediated rejection</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
